Valley National Advisers Inc Amgen Inc Transaction History

Valley National Advisers Inc

  • $674 Million
  • Q2 2024

A detailed history of Valley National Advisers Inc transactions in Amgen Inc stock. As of the latest transaction made, Valley National Advisers Inc holds 23,634 shares of AMGN stock, worth $7.63 Million. This represents 1.1% of its overall portfolio holdings.

Number of Shares
23,634
Previous 24,566 3.79%
Holding current value
$7.63 Million
Previous $6.98 Million 5.71%
% of portfolio
1.1%
Previous 1.06%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024
SELL
$262.75 - $319.31 $244,883 - $297,596
-932 Reduced 3.79%
23,634 $7.38 Million
Q1 2024

Apr 19, 2024
SELL
$268.87 - $324.56 $155,406 - $187,595
-578 Reduced 2.3%
24,566 $6.98 Million
Q4 2023

Jan 25, 2024
SELL
$255.7 - $288.46 $303,771 - $342,690
-1,188 Reduced 4.51%
25,144 $7.24 Million
Q3 2023

Nov 13, 2023
SELL
$218.65 - $271.46 $72,810 - $90,396
-333 Reduced 1.25%
26,332 $7.08 Million
Q2 2023

Jul 31, 2023
SELL
$214.27 - $253.37 $4,713 - $5,574
-22 Reduced 0.08%
26,665 $5.92 Million
Q1 2023

Apr 26, 2023
SELL
$225.79 - $275.2 $48,093 - $58,617
-213 Reduced 0.79%
26,687 $6.52 Million
Q4 2022

Jan 12, 2023
SELL
$229.03 - $291.01 $166,275 - $211,273
-726 Reduced 2.63%
26,900 $7.34 Million
Q3 2022

Nov 08, 2022
BUY
$224.46 - $253.15 $166,549 - $187,837
742 Added 2.76%
27,626 $6.97 Million
Q2 2022

Jul 15, 2022
BUY
$230.71 - $256.74 $28,146 - $31,322
122 Added 0.46%
26,884 $6.65 Million
Q1 2022

May 06, 2022
BUY
$219.27 - $242.57 $80,472 - $89,023
367 Added 1.39%
26,762 $6.47 Million
Q4 2021

Feb 11, 2022
SELL
$198.88 - $227.6 $98,644 - $112,889
-496 Reduced 1.84%
26,395 $5.94 Million
Q3 2021

Nov 10, 2021
SELL
$212.27 - $248.7 $72,596 - $85,055
-342 Reduced 1.26%
26,891 $5.72 Million
Q2 2021

Aug 02, 2021
SELL
$233.58 - $259.14 $40,175 - $44,572
-172 Reduced 0.63%
27,233 $6.64 Million
Q1 2021

May 07, 2021
SELL
$221.91 - $258.6 $126,266 - $147,143
-569 Reduced 2.03%
27,405 $6.82 Million
Q4 2020

Feb 11, 2021
SELL
$216.38 - $257.67 $223,304 - $265,915
-1,032 Reduced 3.56%
27,974 $6.43 Million
Q3 2020

Nov 13, 2020
SELL
$234.65 - $260.95 $260,226 - $289,393
-1,109 Reduced 3.68%
29,006 $7.37 Million
Q2 2020

Aug 10, 2020
SELL
$197.81 - $242.74 $266,647 - $327,213
-1,348 Reduced 4.28%
30,115 $7.1 Million
Q1 2020

May 13, 2020
SELL
$182.24 - $241.7 $302,518 - $401,222
-1,660 Reduced 5.01%
31,463 $6.38 Million
Q4 2019

Feb 13, 2020
BUY
$189.21 - $243.2 $97,443 - $125,248
515 Added 1.58%
33,123 $7.99 Million
Q3 2019

Nov 12, 2019
BUY
$174.11 - $208.62 $538,174 - $644,844
3,091 Added 10.47%
32,608 $6.31 Million
Q2 2019

Aug 08, 2019
BUY
$166.7 - $195.41 $399,913 - $468,788
2,399 Added 8.85%
29,517 $5.44 Million
Q1 2019

Apr 26, 2019
BUY
$180.87 - $203.88 $95,861 - $108,056
530 Added 1.99%
27,118 $5.15 Million
Q4 2018

Feb 25, 2019
BUY
$178.4 - $208.25 $167,874 - $195,963
941 Added 3.67%
26,588 $5.18 Million
Q3 2018

Nov 08, 2018
BUY
$185.29 - $208.89 $216,233 - $243,774
1,167 Added 4.77%
25,647 $5.32 Million
Q2 2018

Aug 14, 2018
BUY
$166.05 - $186.51 $234,794 - $263,725
1,414 Added 6.13%
24,480 $4.52 Million
Q1 2018

Apr 19, 2018
BUY
$169.43 - $198.0 $718,552 - $839,718
4,241 Added 22.53%
23,066 $3.93 Million
Q4 2017

Feb 13, 2018
BUY
$168.79 - $188.59 $949,781 - $1.06 Million
5,627 Added 42.64%
18,825 $3.27 Million
Q3 2017

Nov 14, 2017
BUY
$167.29 - $191.0 $2.21 Million - $2.52 Million
13,198
13,198 $2.46 Million

Others Institutions Holding AMGN

# of Institutions
3,054
Shares Held
409M
Call Options Held
7.19M
Put Options Held
6.26M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $173B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Valley National Advisers Inc Portfolio

Follow Valley National Advisers Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valley National Advisers Inc, based on Form 13F filings with the SEC.

News

Stay updated on Valley National Advisers Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email